We are a venture studio leveraging Alloy’s pre-competitive drug discovery platforms. Established drug discovery, scientific, and lab resources allow entrepreneurs to start their first experiment on day one.
82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large.
The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work.
We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest.
We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed.
We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science.
We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value.
We launch new companies and support strategic investments
Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic.
We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster.
We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future. Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.